These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Dopaminergic modulation of striatal acetylcholine release in rats depleted of dopamine as neonates. Johnson BJ; Bruno JP Neuropharmacology; 1995 Feb; 34(2):191-203. PubMed ID: 7617145 [TBL] [Abstract][Full Text] [Related]
27. Increases in striatal acetylcholine by SKF-38393 are mediated through D1 dopamine receptors in striatum and not the frontal cortex. Zocchi A; Pert A Brain Res; 1993 Nov; 627(2):186-92. PubMed ID: 8298961 [TBL] [Abstract][Full Text] [Related]
28. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Singh NA; Bush LG; Gibb JW; Hanson GR Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780 [TBL] [Abstract][Full Text] [Related]
29. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257 [TBL] [Abstract][Full Text] [Related]
31. Modulation of dopaminergic terminal excitability by D1 selective agents: further characterization. Diana M; Young SJ; Groves PM Neuroscience; 1991; 42(2):441-9. PubMed ID: 1680226 [TBL] [Abstract][Full Text] [Related]
32. CY 208-243 behaves as a typical D-1 agonist in the reserpine-treated mouse. Abbott B; Starr BS; Starr MS Pharmacol Biochem Behav; 1991 Feb; 38(2):259-63. PubMed ID: 1676166 [TBL] [Abstract][Full Text] [Related]
33. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice. Toyoshi T; Ukai M; Kameyama T Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161 [TBL] [Abstract][Full Text] [Related]
34. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
35. D1 receptors function to inhibit the activation of tuberoinfundibular dopamine neurons. Berry SA; Gudelsky GA J Pharmacol Exp Ther; 1990 Aug; 254(2):677-82. PubMed ID: 1974647 [TBL] [Abstract][Full Text] [Related]
37. Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum. Stoof JC; Kebabian JW Brain Res; 1982 Nov; 250(2):263-70. PubMed ID: 6293642 [TBL] [Abstract][Full Text] [Related]
38. Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats. Ikarashi Y; Takahashi A; Ishimaru H; Arai T; Maruyama Y Brain Res Bull; 1997; 43(1):107-15. PubMed ID: 9205804 [TBL] [Abstract][Full Text] [Related]
39. Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum. Consolo S; Girotti P; Russi G; Di Chiara G J Neurochem; 1992 Oct; 59(4):1555-7. PubMed ID: 1402904 [TBL] [Abstract][Full Text] [Related]